A Comparison of Parathyroid Hormone-Related Protein (1–36) and Parathyroid Hormone (1–34) on Markers of Bone Turnover and Bone Density in Postmenopausal Women: The PrOP Study

Abstract

In [1], an author's name was spelled incorrectly. The correct author listing should appear as: Leila Khan.This erratum corrects the error.

The search for the optimal anabolic osteoporosis therapy

“…Earlier, preliminary data collected in short-term and small human studies, (2)(3)(4) as well as preclinical studies, (5) had suggested that PTHrP might increase formation without increasing resorption and provided the rationale for the current randomized trial comparing two doses of PTHrP to teriparatide over 3 months. (1) The absence or near absence of hypercalcemia with comparable doses in those prior studies (2)(3)(4) also suggested that PTHrP might avoid that known potential side effect of PTH therapy.…”

“…Earlier, preliminary data collected in short-term and small human studies, (2)(3)(4) as well as preclinical studies, (5) had suggested that PTHrP might increase formation without increasing resorption and provided the rationale for the current randomized trial comparing two doses of PTHrP to teriparatide over 3 months. (1) The absence or near absence of hypercalcemia with comparable doses in those prior studies (2)(3)(4) also suggested that PTHrP might avoid that known potential side effect of PTH therapy.Horwitz and colleagues (1) show that, indeed, PTHrP has a net anabolic effect with a significant bone formation marker increase over the 3 months of the study. The net effects of PTHrP on BMD over 3 months were indistinguishable from those of teriparatide, although inferences about BMD are limited by the small study size and relatively short duration.…”

“…Horwitz and colleagues (1) show that, indeed, PTHrP has a net anabolic effect with a significant bone formation marker increase over the 3 months of the study. The net effects of PTHrP on BMD over 3 months were indistinguishable from those of teriparatide, although inferences about BMD are limited by the small study size and relatively short duration.…”

“…Cross-linked C-telopeptide (CTX) (the measure of resorption) also increased much more with teriparatide than with PTHrP (92% versus 30%). (1) In terms of safety, the investigators had hypothesized that PTHrP would be less likely to induce hypercalcemia than teriparatide, based on the absence or near absence of hypercalcemia in their prior studies with the doses used here. Surprisingly, the results showed the opposite: PTHrP led to more instances of elevated serum calcium (defined as serum Ca >10.5 mg/dL) than teriparatide.…”

“…The search for such a treatment has been a theme in many interesting clinical studies over the last 10 years. The report by Horwitz and colleagues (1) in this issue of the Journal of Bone and Mineral Research details a 3-month trial of one such approach: PTH related protein (PTHrP ). Earlier, preliminary data collected in short-term and small human studies, (2)(3)(4) as well as preclinical studies, (5) had suggested that PTHrP might increase formation without increasing resorption and provided the rationale for the current randomized trial comparing two doses of PTHrP to teriparatide over 3 months.…”